Travere Therapeutics has crossed from a single-indication immunoglobulin A nephropathy launch into a two-indication rare-kidney franchise, and the second quarter is the first clean look at whether that expansion is commercially real. In April the Food and Drug Administration approved FILSPARI, known chemically as sparsentan, as the first medicine indicated for focal segmental glomerulosclerosis without nephrotic syndrome. That approval, stacked on the earlier full IgAN label, is the event that recasts the equity from a one-disease launch to a platform duration story. A share price in the low sixties already treats a long FILSPARI compounding path as the base case rather than the upside case.
The strategic tension is mix, not existence. FILSPARI already nearly doubled domestic product sales versus the year-ago quarter, yet selling costs jumped with the FSGS launch and a forty million inducement charge on a convertible refinancing pushed the reported net loss wider. Operating income flipped positive for the first time even as the income statement still looks messy underneath. The tape is paying a commercial-stage multiple for a peak-sales path that management has framed above three billion across both labels. That path is only as good as start-form conversion and share defense in a crowding IgAN market.
Just over two thousand new patient start forms arrived in the quarter, more than double the first-quarter IgAN-only print, and domestic FILSPARI sales reached $141 million. Cash at mid-year sat near $489 million before a July licensing payment. The next year resolves whether FSGS demand compounds like the IgAN curve or fades after the initial bolus, and whether IgAN share holds as Novartis and later immunology entrants press the same nephrology call point.